Ensysce Biosciences, Inc. (ENSC) - 10-K Summary
Business Context and Reporting Period
Company: Ensysce Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Ensysce is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protective opioid technologies. Its lead product candidate, PF614 (a TAAP oxycodone prodrug), is in Phase 3 clinical development for acute pain. PF614-MPAR (combining PF614 with nafamostat for overdose protection) is in Phase 1b development and holds FDA Breakthrough Therapy designation. The company has no approved products and no product revenue.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue (Federal Grants) | $5.07 million | $5.21 million |
| Net Loss | $(10.18) million | $(7.99) million |
| Operating Expenses | $15.31 million | $11.94 million |
| Research & Development | $10.38 million | $7.22 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $4.31 million | $3.50 million |
| Net Cash Used in Operating Activities | $(7.81) million | $(7.50) million |
| Net Cash Provided by Financing Activities | $8.74 million | $9.88 million |
Note: The company has no product revenue. Revenue consists entirely of federal grants from NIH/NIDA.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $2.19 million (27%) compared to 2024, driven primarily by a $3.16 million increase in R&D expenses due to expanded clinical and pre-clinical programs for PF614 and PF614-MPAR.
- Revenue Decline: Grant revenue decreased slightly by $0.14 million due to the timing of research activities and the conclusion of the OUD grant in August 2024, partially offset by the new MPAR grant.
- Financing Activity: The company raised significant capital in 2025 through a Series B Preferred Stock financing ($4.0 million aggregate), warrant inducements, and public offerings, resulting in $8.74 million in net cash provided by financing activities.
- Debt Reduction: Interest expense decreased significantly from $1.29 million in 2024 to $18,767 in 2025, as the amortization of the 2023 Notes discount was fully recognized in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. Management estimates current cash resources are sufficient to fund operations only into the second quarter of 2026. Additional financing is required to continue operations.
- Outlook: The company expects to continue incurring significant losses. Future expenses will increase as it advances PF614 into Phase 3 trials and continues development of PF614-MPAR and nafamostat.
- Key Risks:
- Capital Requirements: Failure to raise additional capital could force the company to delay, reduce, or terminate product development.
- Regulatory Approval: No assurance that PF614 or PF614-MPAR will receive FDA approval or achieve commercial success.
- Nasdaq Compliance: As of February 25, 2026, the company received notice of non-compliance with Nasdaq bid price requirements (stock price below $1.00 for 30+ days). It has until August 24, 2026, to regain compliance or face delisting.
- Third-Party Dependence: Reliance on CROs for clinical trials and CMOs for manufacturing.
- Unusual Items:
- Series B Preferred Stock: Issued in November 2025 with complex features including a 4% accruing dividend, liquidation preference, and anti-dilution protections. The company determined embedded derivative features were immaterial.
- Warrant Inducements: Significant warrant inducement transactions occurred in April 2025 and August 2024 to raise capital, involving the issuance of new warrants at reduced exercise prices.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before Q2 2026 to avoid operational curtailment.
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards (bid price) by the August 2026 deadline.
- Grant Funding: Confirm the status of the remaining $7.4 million in NIH MPAR grant funding and the timeline for utilization through May 2027.
- Clinical Milestones: Track enrollment and data readouts for the pivotal Phase 3 trial of PF614 (initiated December 2025) and Phase 1b trial of PF614-MPAR.
- Dilution Risk: Assess the potential dilution from the large number of outstanding warrants (over 3.2 million shares) and the conversion of Series B Preferred Stock.